Table of Content


Introduction
Indoleamine 2,3 Dioxygese 1 (Indoleamine Pyrrole 2,3 Dioxygese 1 or IDO1 or EC 1.13.11.52) - Overview
Indoleamine 2,3 Dioxygese 1 (Indoleamine Pyrrole 2,3 Dioxygese 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development
Indoleamine 2,3 Dioxygese 1 (Indoleamine Pyrrole 2,3 Dioxygese 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment
Indoleamine 2,3 Dioxygese 1 (Indoleamine Pyrrole 2,3 Dioxygese 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development
Indoleamine 2,3 Dioxygese 1 (Indoleamine Pyrrole 2,3 Dioxygese 1 or IDO1 or EC 1.13.11.52) - Drug Profiles
Indoleamine 2,3 Dioxygese 1 (Indoleamine Pyrrole 2,3 Dioxygese 1 or IDO1 or EC 1.13.11.52) - Dormant Products
Indoleamine 2,3 Dioxygese 1 (Indoleamine Pyrrole 2,3 Dioxygese 1 or IDO1 or EC 1.13.11.52) - Discontinued Products
Indoleamine 2,3 Dioxygese 1 (Indoleamine Pyrrole 2,3 Dioxygese 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by BeiGene Ltd, 2021
Pipeline by BirchBioMed Inc, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by CanBas Co Ltd, 2021
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2021
Pipeline by Emcure Pharmaceuticals Ltd, 2021
Pipeline by F. Hoffmann-La Roche Ltd, 2021
Pipeline by Gerologix Inc, 2021
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2021
Pipeline by Hutchison MediPharma Ltd, 2021
Pipeline by Incyte Corp, 2021
Pipeline by IO Biotech ApS, 2021
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Pipeline by Kyowa Kirin Co Ltd, 2021
Pipeline by Lumos Pharma Inc, 2021
Pipeline by Luye Pharma Group Ltd, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Nammi Therapeutics Inc, 2021
Pipeline by Netherlands Translational Research Center BV, 2021
Pipeline by Orpheris Inc, 2021
Pipeline by Phenex Pharmaceuticals AG, 2021
Pipeline by Regen BioPharma Inc, 2021
Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021
Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2021
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021
Pipeline by Syntekabio Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021
Discontinued Products, 2021 (Contd..1)
Discontinued Products, 2021 (Contd..2)